1. Scrip
  2. >>R&D

Ambitious AB Science Gets Masitinib Win For Severe Asthma

Drug In Trials For Seven Indications

 
• By Kevin Grogan

Plagued by concerns on the integrity of data and compliance issues with its clinical practices, the French firm still believes masitinib could be effective for ALS, multiple sclerosis, cancers, asthma and even Alzheimer's.

Eggs_Basket
AB Science has a lot of eggs in its clinical basket • Source: Shutterstock

At long last, AB Science has some good news to share about its lead candidate, masitinib, after the French biotech announced positive top-line late-stage results for the drug in severe asthma.

The Paris-headquartered firm said that a 355-patient Phase III study evaluating oral masitinib, a tyrosine kinase inhibitor (TKI), in severe asthma uncontrolled by oral corticosteroids met its primary endpoint of significantly reducing the rate of severe asthma

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.